Aldeyra Therapeutics (ALDX) Tops Q2 EPS by 4c

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q2 EPS of ($0.35), $0.04 better than the analyst estimate of ($0.39).

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Copart (CPRT) Misses Q4 EPS by 4c
• Skillsoft (SKIL) Tops Q2 EPS by 14c; Offers Guidance